Cargando…
Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension
Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions. The abundance of interleukin-1 (IL-1) is strongly correlated with the severity and long-term...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637286/ https://www.ncbi.nlm.nih.gov/pubmed/31354700 http://dx.doi.org/10.3389/fimmu.2019.01480 |
_version_ | 1783436211920044032 |
---|---|
author | Bui, Christine B. Kolodziej, Magdalena Lamanna, Emma Elgass, Kirstin Sehgal, Arvind Rudloff, Ina Schwenke, Daryl O. Tsuchimochi, Hirotsugu Kroon, Maurice A. G. M. Cho, Steven X. Maksimenko, Anton Cholewa, Marian Berger, Philip J. Young, Morag J. Bourke, Jane E. Pearson, James T. Nold, Marcel F. Nold-Petry, Claudia A. |
author_facet | Bui, Christine B. Kolodziej, Magdalena Lamanna, Emma Elgass, Kirstin Sehgal, Arvind Rudloff, Ina Schwenke, Daryl O. Tsuchimochi, Hirotsugu Kroon, Maurice A. G. M. Cho, Steven X. Maksimenko, Anton Cholewa, Marian Berger, Philip J. Young, Morag J. Bourke, Jane E. Pearson, James T. Nold, Marcel F. Nold-Petry, Claudia A. |
author_sort | Bui, Christine B. |
collection | PubMed |
description | Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions. The abundance of interleukin-1 (IL-1) is strongly correlated with the severity and long-term outcome of BPD infants and we have previously shown that IL-1 receptor antagonist (IL-1Ra) protects against murine BPD; therefore, we hypothesized that IL-1Ra may also be effective against BPD-PH. We employed daily injections of IL-1Ra in a murine model in which BPD/BPD-PH was induced by antenatal LPS and postnatal hyperoxia of 65% O(2). Pups reared in hyperoxia for 28 days exhibited a BPD-PH-like disease accompanied by significant changes in pulmonary vascular morphology: micro-CT revealed an 84% reduction in small vessels (4–5 μm diameter) compared to room air controls; this change was prevented by IL-1Ra. Pulmonary vascular resistance, assessed at day 28 of life by echocardiography using the inversely-related surrogate marker time-to-peak-velocity/right ventricular ejection time (TPV/RVET), increased in hyperoxic mice (0.27 compared to 0.32 in air controls), and fell significantly with daily IL-1Ra treatment (0.31). Importantly, in vivo cine-angiography revealed that this protection afforded by IL-1Ra treatment for 28 days is maintained at day 60 of life. Despite an increased abundance of mediators of pulmonary angiogenesis in day 5 lung lysates, namely vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1), no difference was detected in ex vivo pulmonary vascular reactivity between air and hyperoxia mice as measured in precision cut lung slices, or by immunohistochemistry in alpha-smooth muscle actin (α-SMA) and endothelin receptor type-A (ET(A)) at day 28. Further, on day 28 of life we observed cardiac fibrosis by Sirius Red staining, which was accompanied by an increase in mRNA expression of galectin-3 and CCL2 (chemokine (C-C motif) ligand 2) in whole hearts of hyperoxic pups, which improved with IL-1Ra. In summary, our findings suggest that daily administration of the anti-inflammatory IL-1Ra prevents the increase in pulmonary vascular resistance and the pulmonary dysangiogenesis of murine BPD-PH, thus pointing to IL-1Ra as a promising candidate for the treatment of both BPD and BPD-PH. |
format | Online Article Text |
id | pubmed-6637286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66372862019-07-26 Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension Bui, Christine B. Kolodziej, Magdalena Lamanna, Emma Elgass, Kirstin Sehgal, Arvind Rudloff, Ina Schwenke, Daryl O. Tsuchimochi, Hirotsugu Kroon, Maurice A. G. M. Cho, Steven X. Maksimenko, Anton Cholewa, Marian Berger, Philip J. Young, Morag J. Bourke, Jane E. Pearson, James T. Nold, Marcel F. Nold-Petry, Claudia A. Front Immunol Immunology Pulmonary hypertension secondary to bronchopulmonary dysplasia (BPD-PH) represents a major complication of BPD in extremely preterm infants for which there are currently no safe and effective interventions. The abundance of interleukin-1 (IL-1) is strongly correlated with the severity and long-term outcome of BPD infants and we have previously shown that IL-1 receptor antagonist (IL-1Ra) protects against murine BPD; therefore, we hypothesized that IL-1Ra may also be effective against BPD-PH. We employed daily injections of IL-1Ra in a murine model in which BPD/BPD-PH was induced by antenatal LPS and postnatal hyperoxia of 65% O(2). Pups reared in hyperoxia for 28 days exhibited a BPD-PH-like disease accompanied by significant changes in pulmonary vascular morphology: micro-CT revealed an 84% reduction in small vessels (4–5 μm diameter) compared to room air controls; this change was prevented by IL-1Ra. Pulmonary vascular resistance, assessed at day 28 of life by echocardiography using the inversely-related surrogate marker time-to-peak-velocity/right ventricular ejection time (TPV/RVET), increased in hyperoxic mice (0.27 compared to 0.32 in air controls), and fell significantly with daily IL-1Ra treatment (0.31). Importantly, in vivo cine-angiography revealed that this protection afforded by IL-1Ra treatment for 28 days is maintained at day 60 of life. Despite an increased abundance of mediators of pulmonary angiogenesis in day 5 lung lysates, namely vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1), no difference was detected in ex vivo pulmonary vascular reactivity between air and hyperoxia mice as measured in precision cut lung slices, or by immunohistochemistry in alpha-smooth muscle actin (α-SMA) and endothelin receptor type-A (ET(A)) at day 28. Further, on day 28 of life we observed cardiac fibrosis by Sirius Red staining, which was accompanied by an increase in mRNA expression of galectin-3 and CCL2 (chemokine (C-C motif) ligand 2) in whole hearts of hyperoxic pups, which improved with IL-1Ra. In summary, our findings suggest that daily administration of the anti-inflammatory IL-1Ra prevents the increase in pulmonary vascular resistance and the pulmonary dysangiogenesis of murine BPD-PH, thus pointing to IL-1Ra as a promising candidate for the treatment of both BPD and BPD-PH. Frontiers Media S.A. 2019-07-11 /pmc/articles/PMC6637286/ /pubmed/31354700 http://dx.doi.org/10.3389/fimmu.2019.01480 Text en Copyright © 2019 Bui, Kolodziej, Lamanna, Elgass, Sehgal, Rudloff, Schwenke, Tsuchimochi, Kroon, Cho, Maksimenko, Cholewa, Berger, Young, Bourke, Pearson, Nold and Nold-Petry. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Bui, Christine B. Kolodziej, Magdalena Lamanna, Emma Elgass, Kirstin Sehgal, Arvind Rudloff, Ina Schwenke, Daryl O. Tsuchimochi, Hirotsugu Kroon, Maurice A. G. M. Cho, Steven X. Maksimenko, Anton Cholewa, Marian Berger, Philip J. Young, Morag J. Bourke, Jane E. Pearson, James T. Nold, Marcel F. Nold-Petry, Claudia A. Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title_full | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title_fullStr | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title_full_unstemmed | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title_short | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
title_sort | interleukin-1 receptor antagonist protects newborn mice against pulmonary hypertension |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637286/ https://www.ncbi.nlm.nih.gov/pubmed/31354700 http://dx.doi.org/10.3389/fimmu.2019.01480 |
work_keys_str_mv | AT buichristineb interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT kolodziejmagdalena interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT lamannaemma interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT elgasskirstin interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT sehgalarvind interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT rudloffina interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT schwenkedarylo interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT tsuchimochihirotsugu interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT kroonmauriceagm interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT chostevenx interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT maksimenkoanton interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT cholewamarian interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT bergerphilipj interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT youngmoragj interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT bourkejanee interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT pearsonjamest interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT noldmarcelf interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension AT noldpetryclaudiaa interleukin1receptorantagonistprotectsnewbornmiceagainstpulmonaryhypertension |